ClinicalTrials.gg
Active, not recruitingNCT06261320MESOCOLOUpdated May 31, 2025

Mesotherapy Treatment of Irritable Bowel Syndrome

A Phase 2 interventional study of Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate in Inflammatory Bowel Diseases, sponsored by Polyclinique de l'Europe. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Polyclinique de l'Europe · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 143 studies in Inflammatory Bowel Diseases with a site in France — 31 open to participants now, 42 under way, 7 of them phase 3. Inflammatory Bowel Diseases · France.

Enrollment
71st of 84
27 · median 124
Started
2024
with 11 others
Phase 2
19 of 143
4 open now
Primary completion
2026-12
later than 16 of 41 live
Registered
121st of 143
by date

Among the 143 studies in Inflammatory Bowel Diseases with a site in France, this one is the 71st largest by enrollment of the 84 interventional ones that give a count, is one of 12 that started in 2024, is one of 19 in phase 2, reaches primary completion later than 16 of the 41 other live ones, and was the 121st registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

31 of the 143 studies in Inflammatory Bowel Diseases with a site in France are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Inflammatory Bowel Diseases with a site in France, or all of them as a file.
02

Study summary

Irritable bowel syndrome (IBS) is a gastrointestinal transit disorder characterized by chronic abdominal pain and impaired transit in the absence of demonstrated organic disease. Considered a non-fatal disease, its effects relate more to quality of life, work production and health care systems.

Given the complexity of this disease, no treatment has been recognized as standard treatment. The treatment is rather focused on treating the symptoms caused (chronic pain or intestinal transit disorder). In general, therapy is considered individualized and includes lifestyle/diet modifications and pharmaceutical therapy.

Several published case studies evaluating the effect of mesotherapy on improving the severity of the disease have demonstrated an improvement in the symptoms of this syndrome. Due to the limited number of case studies and the insufficient level of evidence to conclude, our study will therefore be a before-and-after intervention study, to evaluate the effect of four mesotherapy sessions on the treatment of IBS symptoms.

03

Conditions studied

  • Inflammatory Bowel Diseases

Keywords

  • mesotherapy
  • inflammatory bowel disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient suffering from Irritable Bowel Syndrome according to the Rome IV criteria, whose diagnosis was made by a specialist in Hepato-Gastro-Enterology,
  • Francis score >75/500, i.e. minimal, moderate or severe severity,
  • Patient who has failed conventional treatment (treatment followed for at least 1 year and not showing an improvement in symptoms)
  • Absence of risk of ongoing pregnancy in women of childbearing age, validated by a urine test during the first consultation and before treatment and each month during treatment and until 1 month after the end of treatment

Exclusion criteria

Exclusion Criteria:

  • Patient with the following medical history or current pathologies: organic gastrointestinal pathology, disabling neurological pathology, disabling psychiatric pathology
  • Recent Post Traumatic Stress Syndrome (\<1 year),
  • Fibromyalgia syndrome,
  • Known allergy to medications used in mesotherapy treatment,
  • Pregnant or breastfeeding woman
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Experimental group

    Drug: Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate

Interventions

  • DrugMesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate

    4 sessions of mesotherapy (mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate), with intra-epidermal and intra-hypodermal technics.

06

What researchers measure

Primary outcomes

  1. Irritable Bowel Syndrome Symptom Severity Scale(IBS-SSS)

    Includes 5 items regarding pain (intensity and number of days), abdominal distention, satisfaction of bowel habit, and interference of daily life of the last 10 d on a 10-point scale. Gives a score between 0 and 500, and groups of severity can be made: mild (≤175), moderate (175-300), and severe (≥300) IBS.

    Time frame: day 8, day 15, day 30, day 45

Secondary outcomes

  1. Functional Digestive Disorders Quality of Life questionnaire (FDDQL)

    43 items with 8 subscales : daily activity, anxiety, nutrition, sleep, discomfort, health perception, adaptation and impact of stress Global score is between 0 and 100.

    Time frame: day 30, day 45

  2. Pain evaluation

    Evaluation of pain with a scale from 0 (no pain) to 10 (worst pain imagined)

    Time frame: day 8, day 15, day 30, day 45

  3. Global satisfaction

    4 questions with Likert scale of 5 items, to "not at all satisfied" to "very satisfied"

    Time frame: day 45

  4. Anxiety evaluation : Questionnaire "Hospital anxiety and depression scale"

    14 items with 7 about depression and 7 about anxiety. Each item is noted with a Likert scale of 4 points, from 0 (no symptoms) to 3 (strong symptoms).

    Time frame: day 30, day 45

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.

Of 34 non-industry phase 2 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 50. This study's planned 34 months is above that.

Counting every sponsor, half of 61 studies reached it within 27 months; a quarter within 18 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2024
First posted
Feb 15, 2024
StartActual
Feb 28, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 31, 2027
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06261320
Lead sponsor
Polyclinique de l'Europe
Responsible party
Sponsor
First posted
Feb 15, 2024
Start date
Feb 28, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
May 31, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion